Silence Therapeutics plc Cost of Revenue
Silence Therapeutics plc (SLN) reported Cost of Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-10
- Silence Therapeutics plc cost of goods and services sold for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Silence Therapeutics plc cost of goods and services sold for the quarter ending 2026-03-31 was $11.00K, a 79.63% decline year-over-year.
- Silence Therapeutics plc cost of goods and services sold for the quarter ending 2025-12-31 was $12.00K, a 99.41% decline year-over-year.
- Silence Therapeutics plc cost of goods and services sold for the quarter ending 2025-09-30 was $64.00K, a 98.24% decline year-over-year.
- Silence Therapeutics plc cost of goods and services sold for fiscal 2025 was $215.00K, a 98.18% decline from fiscal 2024.
- Silence Therapeutics plc cost of goods and services sold for fiscal 2024 was $11.81M, a 8.21% decline from fiscal 2023.
- Silence Therapeutics plc cost of goods and services sold for fiscal 2023 was $12.87M, a 4.43% decline from fiscal 2022.
- Silence Therapeutics plc cost of goods and services sold for fiscal 2022 was $13.46M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 | $11.00K 10-Q · filed 2026-08-10 | $23.00K derived: sum of 3 quarters · filed 2026-08-10 | $87.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $11.00K 10-Q · filed 2026-05-07 | $23.00K derived: sum of 2 quarters · filed 2026-05-07 | $87.00K derived: sum of 3 quarters · filed 2026-05-07 | $172.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $76.00K derived: sum of 2 quarters · filed 2026-03-05 | $161.00K derived: sum of 3 quarters · filed 2026-08-10 | $215.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $64.00K 10-Q · filed 2025-11-06 | $149.00K derived: sum of 2 quarters · filed 2026-08-10 | $203.00K 10-Q · filed 2025-11-06 | $2.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $85.00K 10-Q · filed 2026-08-10 | $139.00K 10-Q · filed 2026-08-10 | $2.18M derived: sum of 3 quarters · filed 2026-08-10 | $5.82M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $54.00K 10-Q · filed 2026-05-07 | $2.09M derived: sum of 2 quarters · filed 2026-05-07 | $5.73M derived: sum of 3 quarters · filed 2026-05-07 | $9.06M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.68M derived: sum of 2 quarters · filed 2026-03-05 | $9.01M derived: sum of 3 quarters · filed 2026-03-05 | $11.81M 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.64M 10-Q · filed 2025-11-06 | $6.97M derived: sum of 2 quarters · filed 2025-11-06 | $9.77M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $3.33M 10-Q · filed 2025-08-07 | $6.13M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $2.80M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $12.87M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $13.46M 10-K · filed 2025-02-27 |